Bueno, Maria JoseMouron, SilvanaCaleiras, EduardoMartínez, MarioManso, LuisColomer, RamónQuintela-Fandino, Miguel2024-09-162024-09-162024-05Clin Transl Oncol . 2024;26(5):1273-1279.https://hdl.handle.net/20.500.12105/23122BACKGROUND: HER2, TROP2 and PD-L1 are novel targets in triple-negative breast cancer (TNBC). The combined expression status of these targets, and whether they can define prognostic subgroups, is currently undefined. METHODS: Immunohistochemistry was used to determine HER2, TROP2 and PD-L1 levels in 459 TNBC cases, that received in the adjuvant/neoadjuvant setting active surveillance, CMF, anthracycline-, anthracycline plus taxane-, or carboplatin-containing regimes. RESULTS: HER2-low patients with PD-L1 > 1 CPS (double-positive, herein "DP") had a mean PFS of 4768ﾠdays (95% CI: 4267-5268) versus 3522ﾠdays (95% CI: 3184-3861) for non-DP patients (P = 0.002). Regarding the received adjuvant treatment, DP patients (versus non-DP) receiving anthracyclines plus taxanes exhibited a mean PFS time of 4726 (95% CI: 4022-5430) versus 3302 (95% CI: 2818-3785) days (P = 0.039). Finally, 100% of DP patients that received a carboplatin-based regimen were long-term disease-free. CONCLUSIONS: Early HER2-low, PD-L1-positive TNBC patients have a very good prognosis, particularly if treated with anthracycline/taxane- or carboplatin-containing regimes.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/Triple Negative Breast NeoplasmsBridged-Ring CompoundsTaxoidsHumansCarboplatinB7-H1 AntigenAnthracyclinesAntibiotics, AntineoplasticNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsAttribution-NonCommercial-NoDerivatives 4.0 Internacional37851244265127310.1007/s12094-023-03329-91699-3055Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexicoopen access